ClariVest Asset Management’s Regeneron Pharmaceuticals REGN Stock Holding History

ClariVest Asset Management’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	$1.05K	Hold	1	–	–	﹤0.01%	614
2024 Q2	$1.05K	Hold	1	–	–	﹤0.01%	614
2024 Q1	$966	Hold	1	–	–	﹤0.01%	669
2023 Q4	$882	Hold	1	–	–	﹤0.01%	695
2023 Q3	$1K	Buy	+1	New	+$786	﹤0.01%	705
2022 Q1	–	Sell	-19	Closed	-$12K	–	774
2021 Q4	$12K	Hold	19	–	–	﹤0.01%	521
2021 Q3	$11K	Sell	19 -900	-98%	-$559K	﹤0.01%	525
2021 Q2	$514K	Hold	919	–	–	0.02%	427
2021 Q1	$435K	Buy	919 +300	+48%	+$146K	0.02%	434
2020 Q4	$299K	Sell	619 -182	-23%	-$98.2K	0.01%	464
2020 Q3	$449K	Buy	801 +800	+80,000%	+$485K	0.01%	367
2020 Q2	$1K	Hold	1	–	–	﹤0.01%	754
2020 Q1	$0	Buy	+1	New	+$412	﹤0.01%	763
2013 Q3	–	Sell	-28,183	Closed	-$6.34M	–	591
2013 Q2	$6.34M	Buy	+28,183	New	+$6.56M	0.28%	99

Other funds holding REGN

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

ClariVest Asset Management's REGN Position: Q3 2024 in Review

ClariVest Asset Management held its Regeneron Pharmaceuticals (REGN) position steady in Q3 2024 at 1 share worth $1.05K. The position accounts for ﹤0.01% of the portfolio, ranked #614.

ClariVest Asset Management first reported a position in REGN in Q2 2013 and has held it in 14 quarters since. The position peaked at $6.34M in Q2 2013. 1,389 funds tracked by Wall St. Rank hold REGN as of Q3 2024.

ClariVest Asset Management held 1 share of Regeneron Pharmaceuticals worth $1.05K as of Q3 2024.
ClariVest Asset Management left its Regeneron Pharmaceuticals share count unchanged in Q3 2024.
Regeneron Pharmaceuticals made up ﹤0.01% of ClariVest Asset Management's portfolio in Q3 2024, its #614 holding.
ClariVest Asset Management first reported a position in Regeneron Pharmaceuticals in Q2 2013 and has held it in 14 quarters since.
ClariVest Asset Management's Regeneron Pharmaceuticals position peaked at $6.34M in Q2 2013.
1,389 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2024.

Based on ClariVest Asset Management's 13F filing for Q3 2024, filed 12 Nov 2024.